Clinical Trials Logo

Clinical Trial Summary

The goal of this clinical trial is to to clarify which is the best dose of administration, to select a dose and to confirm the therapeutic efficacy of clodronate in patients with painful knee osteoarthritis (OA). The clinical trial will be divided in two parts. The main questions it aims to answer are: - in Phase II, to assess the safety and tolerability of different escalating doses of intra articular (IA) clodronate - in Phase II, to set a defined therapeutic dose (DTD) to be used in Phase III - in Phase III, to assess the safety and tolerability of different escalating doses of IA clodronate to confirm and extensively evaluate the therapeutic efficacy and safety of the clodronate DTD in patients with knee OA


Clinical Trial Description

The phase II will be a multicenter, double-blind, randomized, placebo-controlled, parallel group four-arm study, according to the treatment dose (dose finding). Briefly, 4 groups of 74 patients (in order to have 64 fully evaluated patients taking into consideration 10 patients dropped out), i.e. a total of 296 patients, with knee OA each will be randomly allocated to the following treatments: 1. IA clodronate 2 mg/2 ml once a week for 4 weeks (total clodronate dose = 8 mg). 2. IA clodronate 5 mg/2 ml once a week for 4 weeks (total clodronate dose = 20 mg). 3. IA clodronate 10 mg/2 ml once a week for 4 weeks (total clodronate dose = 40 mg). 4. Placebo 2 ml once a week for 4 weeks (total clodronate dose = 0 mg). At the end of phase II, the minimum effective clodronate dose will be selected as DTD for the Phase III. The phase III will be a multicenter, double-blind, randomized, placebo-controlled, two parallel groups (DTD vs. placebo) study. Briefly, patients with knee OA will be randomly assigned to two experimental groups: 1. the DTD defined during the Phase II. 2. Matching placebo. The sample size of Phase III will be definitively calculated according to the extent of pain Visual Analogue Scale (VAS) reduction observed in the Phase II. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT06263517
Study type Interventional
Source SPA Società Prodotti Antibiotici S.p.A.
Contact Maria Rosa Galmozzi
Phone 0289139429
Email mariarosa.galmozzi@spafarma.com
Status Recruiting
Phase Phase 2/Phase 3
Start date October 12, 2023
Completion date October 2025

See also
  Status Clinical Trial Phase
Not yet recruiting NCT03274713 - Efficacy of Electro-acupuncture Versus Manual Acupuncture on Knee Osteoarthritis N/A
Completed NCT04535596 - Blood Flow Restriction Exercises and Conservative Exercises in Knee Osteoarthritis N/A
Completed NCT03918291 - Whole-body Vibration Training on Functional Performance of the Elderly With Knee Osteoarthritis N/A
Completed NCT01453738 - Allogeneic Mesenchymal Stem Cells in Osteoarthritis Phase 2
Active, not recruiting NCT01027819 - Comparison of Outcomes in Mobile and Fixed-bearing Total Knee Arthroplasty Phase 4
Completed NCT01186211 - Feasibility of Outpatient Total Knee Arthroplasty
Active, not recruiting NCT00261066 - Outcome Following Orthopaedic Surgery
Completed NCT03484910 - Biofeedback With Cycling Exercise in OA Knee Patients N/A
Recruiting NCT03884374 - Pain Relief for OsteoArthritis Through Combined Treatment (PROACT) N/A
Completed NCT03492320 - Progression of Health Related Quality of Life of Patients Waiting for Total Knee Arthroplasty
Completed NCT01449552 - Temporary Clamping of Drains Combined With Tranexamic Acid Reduce Blood Loss After TKA: A Prospective RCT N/A
Completed NCT06254976 - Serum Nesfatin-1 and Human Cartilage Glycoprotein-39 Levels in Knee Osteoarthritis N/A
Completed NCT03428893 - Mobile Technology to Support Physical Therapy Exercise N/A
Completed NCT05081921 - Clinical Trial to Evaluate Safety and Efficacy of MesoCellA-Ortho Tissue-Engineered Advanced Therapy Product in Patients With Osteoarthrosis and Civilisation Diseases Phase 1/Phase 2
Completed NCT02850068 - Geniculate Artery Embolization for the Treatment of Knee Pain N/A
Active, not recruiting NCT03110172 - Short-term Efficacy of Antidepressant in Patients Underwent TKA Phase 1/Phase 2
Enrolling by invitation NCT02623660 - Microcurrent Stimulation Reduces Post-Operative Swelling and Healing Time Following Knee Replacement Surgery N/A
Completed NCT02579174 - Total Knee Replacement Component Alignment Using Manual Versus Custom Instrumentation N/A
Completed NCT00790985 - Efficacy of Flavocoxid 500 mg Compared With Naproxen 500 mg in Subjects With Moderate-severe Osteoarthritis of the Knee N/A
Recruiting NCT02722772 - Efficacy of Intra-Articular Injection of Etanercept for Moderate and Severe Knee Osteoarthritis N/A